Healthy Skepticism Library item: 19691

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Braillon A
Implementing US-style anti-fraud laws in the Australian pharmaceutical and health care industries
MJA 2011; 195:(10):585
http://www.mja.com.au/public/issues/195_10_211111/letters_211111_fm-9.html

Abstract:

To the Editor: Faunce and colleagues wisely called for the introduction of legislation modelled on the United States False Claims Act (FCA) in the Australian health care setting.1 Indeed, whistleblowers require protection and reward.2 The authors stated that the “key strengths of the US qui tam anti-fraud regime … lie in its recovery of large amounts of public monies, its encouragement of good corporate practice” and noted that it is “largely compensatory or remedial rather than punitive”.2 However, the non-punitive nature of the regime is problematic.